A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 [dovitinib] in Subjects With Acute Myeloid Leukemia.

Trial Profile

A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 [dovitinib] in Subjects With Acute Myeloid Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2010

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2008 Acutal patient numbers, start date, and end date updated as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Status change
    • 25 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top